SOMATROPIN
Generic Name: Somatropin
Pharmacologic Class: Recombinant human growth hormone (hGH) for subcutaneous injection.

PRODUCT NAME & PACKAGING

Product Name: Somatropin
Generic Name: Somatropin
Strength & Packaging: Human Growth Hormone; commercial presentations vary by manufacturer and may include refrigerated vials, cartridges, or pen systems for subcutaneous administration.

PRODUCT DESCRIPTION

Somatropin is a recombinant form of human growth hormone used as replacement therapy when endogenous growth hormone is deficient and for selected short-stature or growth-failure conditions. It is supplied as an injectable biologic and should be used under the supervision of a qualified healthcare professional. Exact approved uses may differ by manufacturer and product label.

INDICATIONS

Common labeled uses include:

• Pediatric growth failure due to growth hormone deficiency
• Short stature associated with Turner syndrome
• Idiopathic short stature
• Small for gestational age with inadequate catch-up growth
• Certain adult patients with growth hormone deficiency

Some somatropin products also carry additional labeled indications, so the exact indication set should be confirmed against the specific brand being dispensed.

DOSAGE & ADMINISTRATION

Route: Subcutaneous injection.
Administration guidance: Dose is individualized according to the patient’s condition, age, body weight, treatment response, and product-specific prescribing information. Somatropin is commonly administered on a scheduled daily basis, often in the evening depending on the formulation and clinical plan. Injection sites should be rotated to reduce the risk of lipoatrophy. Use only as prescribed by the treating clinician.

MECHANISM OF ACTION

Somatropin binds to growth hormone receptors on target cells and triggers intracellular signaling. Its effects are mediated both directly and indirectly through increased production of insulin-like growth factor 1 (IGF-1). These actions support linear growth, protein synthesis, and lipolysis, and contribute to growth-plate stimulation in pediatric patients.

PRECAUTIONS

Use with caution in patients with a history of malignancy, glucose intolerance or diabetes, intracranial hypertension risk, hypothyroidism, hypoadrenalism, or pancreatitis. Somatropin is contraindicated in acute critical illness, active malignancy, severe diabetic retinopathy, known hypersensitivity to the product, and in pediatric patients with closed epiphyses. Certain pediatric patients with Prader-Willi syndrome have additional serious restrictions and warnings.

SIDE EFFECTS

Reported adverse effects may include:

• Injection-site reactions
• Headache
• Muscle or joint pain
• Edema or peripheral edema
• Paresthesia
• Upper respiratory symptoms, fever, or pharyngitis
• Hypothyroidism
• Carpal tunnel syndrome
• Pancreatitis and glucose intolerance in some patients

Patients should be monitored for serious symptoms such as visual changes, severe abdominal pain, breathing difficulty, allergic reactions, or persistent hip/knee pain.

STORAGE

Store refrigerated at 2°C to 8°C (36°F to 46°F) and protect from light as directed by the specific product label. Do not freeze. In-use storage limits vary by brand and presentation, so dispensing staff should verify the exact product instructions before release.